Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $169 | $155 | $125 | $150 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Cost of Goods Sold | $21 | $15 | $12 | $15 |
| Gross Profit | $148 | $139 | $114 | $135 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| R&D Expenses | $23 | $61 | $28 | $30 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $90 | $85 | $92 | $87 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $4 | $2 | $2 |
| Operating Expenses | $113 | $149 | $122 | $119 |
| Operating Income | $34 | -$9 | -$8 | $16 |
| % Margin | 20.3% | -6.1% | -6.3% | 10.7% |
| Other Income/Exp. Net | $0 | -$10 | -$10 | -$8 |
| Pre-Tax Income | $34 | -$19 | -$18 | $8 |
| Tax Expense | $17 | $5 | $4 | -$7 |
| Net Income | $17 | -$24 | -$22 | $15 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 170.1% | -14.3% | -242% | – |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| Weighted Avg Shares Out | 308 | 308 | 308 | 299 |
| Weighted Avg Shares Out Dil | 310 | 308 | 308 | 299 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $12 | $12 | $11 | $12 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $48 | -$6 | -$5 | $22 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |